Hims & Hers Health, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Argus raised its target price for Hims & Hers Health, Inc. (HIMS) to $32.00. The company operates a telehealth platform offering treatments for various health specialties, including erectile dysfunction, hair loss, and mental health.
Hims & Hers Health (HIMS) reported 38% revenue growth to $753M, raised 2026 guidance to $3.1B-$3.3B, and completed Eucalyptus acquisition. However, margins and cash flow declined, with a $86M net loss and $36M negative cash flow. Management expects near-term margin pressure. Hedge fund interest grew, but short interest remains high at 28.3%.
Okupe Oluyemi (Chief Financial Officer) sold 29,277 shares of Hims & Hers Health, Inc. (HIMS) at $29.95 ($0.88M total) on 2026-09-22 under a Rule 10b5-1 trading plan.
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning HIMS (Hims & Hers Health, Inc.). Coverage has skewed bearish: 1 bullish, 2 neutral, and 2 bearish.
Recent HIMS coverage spans financial news, regulation and insider activity.
In the last 30 days, HIMS insiders filed 6 SEC Form 4 transactions — no purchases and 6 sales ($2.1M). The most active reporter was Boughton Soleil, Chief Legal Officer, with 2 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Potential upside as target price increase may attract buyers.
No new material information; reiterates prior earnings.
This is an insider open-market sale by the CFO, but it is explicitly under a pre-arranged 10b5-1 plan, reducing signal strength.
Potential legal penalties and increased compliance costs could pressure Hims & Hers' stock.
Minor dilution from insider sale; limited price impact expected.
AlphAI scores every news story that mentions HIMS with an AI model for sentiment and relevance, and aggregates insider trades from Hims & Hers Health, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Argus raised its target price for Hims & Hers Health, Inc. (HIMS) to $32.00. The company operates a telehealth platform offering treatments for various health specialties, including erectile dysfunction, hair loss, and mental health.
1 min readHims & Hers Health (HIMS) reported 38% revenue growth to $753M, raised 2026 guidance to $3.1B-$3.3B, and completed Eucalyptus acquisition. However, margins and cash flow declined, with a $86M net loss and $36M negative cash flow. Management expects near-term margin pressure. Hedge fund interest grew, but short interest remains high at 28.3%.
2 min readOkupe Oluyemi (Chief Financial Officer) sold 29,277 shares of Hims & Hers Health, Inc. (HIMS) at $29.95 ($0.88M total) on 2026-09-22 under a Rule 10b5-1 trading plan.
2 min readThe FTC, along with California and Utah regulators, filed a lawsuit against Hims & Hers on July 29, alleging privacy risks related to health data-sharing. The complaint was filed in the U.S. District Court for the Northern District of California. This legal action highlights concerns over consumer data protection in the health sector.
1 min readHims & Hers officer Okupe Oluyemi filed a Rule 144 notice to sell 29,277 Class A shares, worth $876,846.15, acquired via options and restricted stock vesting. The company has 224,935,790 Class A shares outstanding as of September 22, 2026, according to the filing.
1 min readThe FTC sued Hims & Hers for allegedly disclosing customer health data, signing users up for hard-to-cancel subscriptions, and bypassing real-time doctor consultations. Hims disputes the claims. Experts note federal laws often don't apply to telehealth companies, leading to data sharing with advertisers. Recent studies found many telehealth services lack proper physician consultations, especially for GLP-1 drugs. State laws offer some protections, but enforcement is limited. Privacy experts reco
2 min readHims & Hers CFO Oluyemi Okupe sold 12,313 shares for $354,860 at $28.82 each, per a 10b5-1 plan. HIMS stock is down 57% from its 52-week high. Analysts have mixed views: Truist raised its target to $32 (Hold), Barclays cut its target to $35 (citing margin pressure). The company launched GLP-1 medications in Australia but faces credit card dispute issues.
2 min readHims & Hers Health (HIMS) stock fell 4% on Tuesday despite record subscriber growth and a Q2 revenue beat. Revenue rose 38% to $753M, but adjusted EBITDA dropped 27% to $60.3M. Morningstar noted margin concerns, while Deutsche Bank raised its price target to $26. The company raised its 2026 revenue forecast but lowered its EBITDA guidance.
2 min readHims & Hers (HIMS) officer Oluyemi Okupe plans to sell 12,313 Class A shares, valued at $354,860.66, on September 17, 2026. The shares were acquired via restricted stock vesting on August 15, 2026. As of September 17, 2026, HIMS had 224,935,790 Class A shares outstanding.
1 min readHims offers Hard Mints, a chewable erectile dysfunction treatment, alongside other ED options. The company provides online consultations, personalized treatment plans, and discreet shipping. Pricing starts at less than $2 a day, with subscription options. All treatments require a prescription after an online consultation with a licensed healthcare provider.
2 min read
